Cite
HARVARD Citation
Bernstein, J. et al. (2020). Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet. 8 (5), pp. 461-474. [Online].